CPA
CYTK icon

Capital Performance Advisors’s Cytokinetics CYTK Stock Holding History

Capital Performance Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8
Closed -$422 – 799
2024
Q3 		$422 Buy
+8
New +$446 ﹤0.01% 2324

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Capital Performance Advisors's CYTK Position: Q4 2024 in Review

Capital Performance Advisors sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 8 shares — an estimated $422 sold.

Capital Performance Advisors first reported a position in CYTK in Q3 2024 and held it in 1 quarter. The position peaked at $422 in Q3 2024. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

  • Capital Performance Advisors reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 8 Cytokinetics shares in Q4 2024, an estimated $422.
  • Capital Performance Advisors first reported a position in Cytokinetics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Cytokinetics position peaked at $422 in Q3 2024.
  • 346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.